Newbury Pharmaceuticals AB (publ) (STO:NEWBRY)
Sweden · Delayed Price · Currency is SEK 1.665
+0.145 (9.54%)
Nov 4, 2026, 5:25 PM CET
STO:NEWBRY Revenue
In the fiscal year ending August 31, 2026, Newbury Pharmaceuticals AB had annual revenue of 44.39M SEK with 29.76% growth. Newbury Pharmaceuticals AB had revenue of 13.92M in the quarter ending August 31, 2026, with 125.89% growth. That makes Newbury Pharmaceuticals AB the 40,296th largest company in the world by revenue and 570th in Sweden.
Revenue
44.39M
Revenue Growth
+29.76%
P/S Ratio
1.08
Revenue / Employee
6.34M
Employees
7
Market Cap
50.61M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2026 | 44.39M | 10.18M | 29.76% |
| Aug 31, 2025 | 34.21M | -5.53M | -13.91% |
| Aug 31, 2024 | 39.74M | 28.57M | 255.77% |
| Aug 31, 2023 | 11.17M | 3.93M | 54.27% |
| Aug 31, 2022 | 7.24M | 4.40M | 154.93% |
| Aug 31, 2021 | 2.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| EQL Pharma AB | 432.35M |
| Enzymatica AB | 51.49M |
| Cinclus Pharma Holding AB | 35.18M |
| Moberg Pharma AB | 16.76M |
| Orexo AB | 12.50M |
| Enorama Pharma AB | 1.45M |
| Dicot Pharma AB | 200.00K |
| Klaria Pharma Holding AB (publ.) | 100.00K |
Newbury Pharmaceuticals AB News
- 7 days ago - Newbury Pharmaceuticals AB Quarterly report: Q4 2026 - Filings
- 3 months ago - Newbury Pharmaceuticals AB Quarterly report: Q3 2026 - Filings
- 6 months ago - Newbury Pharmaceuticals AB Quarterly report: Q2 2026 - Filings
- 7 months ago - Newbury Pharmaceuticals AB Slides: FY 2026 - Filings
- 9 months ago - Newbury Pharmaceuticals AB Quarterly report: Q1 2026 - Filings